ivWatch Extends Patient Monitor to International Markets

ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, has announced a new international partner to manage distribution to support market expansion outside of the United States.
 
Following the CE marking of the ivWatch Model 400, the company signed an agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories, as its distributor for Australia and New Zealand.
 
“Our entry into these markets is a response to growing awareness and clinical demand,” said Scott Hensley, vice president of Sales and Business Development at ivWatch. “We are now poised to meet the ongoing customer requests for our technology as they seek cutting-edge solutions to address the global problem of patient harm caused by peripheral IV infiltration.”
 
Upon completion of regulatory approval requirements for these markets, the ivWatch Model 400 system will be available for the new distributor to introduce clinicians to continuous monitoring to improve patient safety. The company has obtained ISO 13485:2016 certification through the Medical Device Single Audit Program (MDSAP). MDSAP is a global standard for medical device quality management systems in which many international partners participate including the Therapeutic Goods Administration of Australia.
 
“Australia is home to vascular access leaders who are undertaking significant scientific research focused on combating IV therapy complications internationally,” said Paul Williams, director of New Medical. “We’re excited to put our technical teams in place to serve the needs of our customers. Our progressive health care market is equipped to make reliable early detection and notifications of this common IV complication a part of their efforts toward improving patient safety and outcomes.”

ivWatch LLC is a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Its team is focused on eliminating patient harm caused by infiltrations and extravasations. Through the company’s monitored IV solutions, it helps minimize the risks associated with adverse IV events.